TY - JOUR
T1 - USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
AU - Deutsch, Alana
AU - Lacouture, Mario
AU - Andriessen, Anneke
AU - Choi, Jennifer N.
AU - Ho, Alice Y.
AU - McLellan, Beth N.
AU - Mitchell, Edith
AU - Leventhal, Jonathan S.
N1 - Publisher Copyright:
© 2023 Journal of Drugs in Dermatology. All rights reserved.
PY - 2023/11
Y1 - 2023/11
N2 - Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI). Cutaneous immune related adverse events (cirAEs) from ICIs are common and include pruritus as well as maculopapular, eczematous, bullous, lichenoid, and psoriasiform reactions. All clinicians interfacing with cancer patients must expedite proper evaluation and diagnosis, treatment, and/or consultation that supports the need for evidence-directed guidelines. Materials and Methods: A panel of advisors was selected, and a systematic literature review generated foundational evidence to develop a treatment algorithm for cirAEs via a modified Delphi process. Iterations of the algorithm were performed until the group met consensus. Results: An algorithm that tailors the management of cirAEs was developed based on the CTCAE v.5 grading of skin disorders. Representative clinical images and suggested diagnostic measures, supplement the algorithm. Conclusion: Recognition and treatment of cirAEs guided through a multidisciplinary, physician-developed algorithm will limit disruption of immunotherapy, optimize quality of life, and enhance overall outcomes in patients treated with ICIs.
AB - Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI). Cutaneous immune related adverse events (cirAEs) from ICIs are common and include pruritus as well as maculopapular, eczematous, bullous, lichenoid, and psoriasiform reactions. All clinicians interfacing with cancer patients must expedite proper evaluation and diagnosis, treatment, and/or consultation that supports the need for evidence-directed guidelines. Materials and Methods: A panel of advisors was selected, and a systematic literature review generated foundational evidence to develop a treatment algorithm for cirAEs via a modified Delphi process. Iterations of the algorithm were performed until the group met consensus. Results: An algorithm that tailors the management of cirAEs was developed based on the CTCAE v.5 grading of skin disorders. Representative clinical images and suggested diagnostic measures, supplement the algorithm. Conclusion: Recognition and treatment of cirAEs guided through a multidisciplinary, physician-developed algorithm will limit disruption of immunotherapy, optimize quality of life, and enhance overall outcomes in patients treated with ICIs.
UR - http://www.scopus.com/inward/record.url?scp=85176426935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176426935&partnerID=8YFLogxK
U2 - 10.36849/JDD.SF389716
DO - 10.36849/JDD.SF389716
M3 - Article
C2 - 37943279
AN - SCOPUS:85176426935
SN - 1545-9616
VL - 22
SP - S3-S10
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 11
ER -